✦ LIBER ✦

Placebo-Controlled Study of a Humanized Anti-TAC Monoclonal Antibody in Dual Therapy for Prevention of Acute Rejection After Renal Transplantation

✍ Scribed by B Charpentier; E Thervet

Book ID: 117236112
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 133 KB
Volume: 30
Category: Article
ISSN: 0041-1345
DOI: 10.1016/s0041-1345(98)00264-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized, placebo-controlled, double-b

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

✍ Michael Boeckh; Raleigh A. Bowden; Barry Storer; Nelson J. Chao; Ricardo Spielbe 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 957 KB

A PLACEBO CONTROLLED STUDY OF MYCOPHENOL

A PLACEBO CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL USED IN COMBINATION WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR THE PREVENTION OF ACUTE REJECTION IN RENAL ALLOGRAFT RECIPIENTS: 1-YEAR RESULTS

✍ Wiesel, M.; Carl, S. 📂 Article 📅 1998 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 739 KB

Rationale and design of the RIACT–study:

Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

✍ Lena Schiffer, Mario Schiffer, Saskia Merkel, Anke Schwarz, Michael Mengel, Chri 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 454 KB

Can a combined screening/treatment progr

Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial

✍ Dorling, Anthony; Rebollo-Mesa, Irene; Hilton, Rachel; Peacock, Janet L; Vaughan 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 896 KB

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views